Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3355) 3355
Publication (352) 352
Book Review (33) 33
Book Chapter (17) 17
Magazine Article (11) 11
Conference Proceeding (8) 8
Government Document (3) 3
Trade Publication Article (3) 3
Data Set (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Paper (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sofosbuvir (2337) 2337
index medicus (2069) 2069
humans (1970) 1970
hepatitis c (1596) 1596
hepatitis c virus (1392) 1392
antiviral agents - therapeutic use (1225) 1225
ribavirin (1216) 1216
gastroenterology & hepatology (1121) 1121
hepatitis c, chronic - drug therapy (1106) 1106
male (1012) 1012
female (932) 932
middle aged (888) 888
hepatitis (884) 884
interferon (795) 795
hepacivirus - genetics (766) 766
genotype (742) 742
ledipasvir (716) 716
hcv (704) 704
drug therapy, combination (703) 703
antiviral agents (688) 688
treatment outcome (671) 671
infection (630) 630
cirrhosis (578) 578
hepatitis c - drug therapy (566) 566
virus-infection (558) 558
adult (551) 551
aged (531) 531
health aspects (531) 531
infectious diseases (517) 517
therapy (513) 513
sofosbuvir - therapeutic use (490) 490
hepacivirus - drug effects (483) 483
pharmacology & pharmacy (478) 478
liver (467) 467
antiviral agents - administration & dosage (450) 450
ribavirin - therapeutic use (450) 450
sustained virological response (439) 439
patients (430) 430
care and treatment (420) 420
infections (414) 414
antiviral agents - adverse effects (407) 407
genotype 1 infection (407) 407
drug therapy (403) 403
analysis (402) 402
daclatasvir (400) 400
hepatitis c, chronic - virology (389) 389
liver cirrhosis (363) 363
virology (342) 342
genotype 1 (340) 340
uridine monophosphate - analogs & derivatives (340) 340
sustained virologic response (336) 336
direct-acting antivirals (327) 327
simeprevir (321) 321
viruses (314) 314
genotype & phenotype (309) 309
treatment-naive patients (305) 305
transplantation (295) 295
virus diseases (295) 295
biological response modifiers (293) 293
liver transplantation (282) 282
hepatitis-c virus (268) 268
medicine, general & internal (264) 264
hepatitis c, chronic - complications (258) 258
genotypes (256) 256
genetic aspects (254) 254
pegylated interferon (252) 252
immunology (247) 247
abridged index medicus (244) 244
uridine monophosphate - therapeutic use (243) 243
sofosbuvir - administration & dosage (241) 241
treatment-naive (241) 241
efficacy (240) 240
hepatology (239) 239
hcv infection (236) 236
open-label (233) 233
gastroenterology and hepatology (230) 230
plus ribavirin (227) 227
microbiology (224) 224
united-states (222) 222
antiviral agents - pharmacology (216) 216
sofosbuvir plus ribavirin (215) 215
prevalence (214) 214
medical research (213) 213
liver diseases (212) 212
antiviral therapy (211) 211
hepatitis c - virology (211) 211
retrospective studies (210) 210
ribavirin - administration & dosage (209) 209
velpatasvir (208) 208
hepacivirus (206) 206
sofosbuvir - adverse effects (201) 201
benzimidazoles - therapeutic use (199) 199
combination (198) 198
recurrence (197) 197
chronic hepatitis-c (196) 196
safety (195) 195
young adult (195) 195
research (194) 194
telaprevir (192) 192
viral load (191) 191
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3208) 3208
Korean (59) 59
German (49) 49
Spanish (28) 28
French (14) 14
Hungarian (10) 10
Chinese (6) 6
Czech (5) 5
Japanese (5) 5
Russian (2) 2
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
by Svarovskaia, Evguenia S and Gane, Edward and Dvory-Sobol, Hadas and Martin, Ross and Doehle, Brian and Hedskog, Charlotte and Jacobson, Ira M and Nelson, David R and Lawitz, Eric and Brainard, Diana M and McHutchison, John G and Miller, Michael D and Mo, Hongmei
Journal of Infectious Diseases, ISSN 0022-1899, 04/2016, Volume 213, Issue 8, pp. 1240 - 1247
Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration studies.... 
sofosbuvir | L159F | V321A | direct-acting antivirals | resistance | HCV NS5B sofosbuvir resistance-associated variants | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Hepacivirus - genetics | Sequence Analysis, RNA | Molecular Epidemiology | Antiviral Agents - adverse effects | Hepatitis C - epidemiology | Hepatitis C - virology | Drug Resistance, Viral - drug effects | High-Throughput Nucleotide Sequencing | Sofosbuvir - adverse effects | Genotype | Care and treatment | Interferon | Dosage and administration | Research | Hepatitis C | Major and Brief Reports | HCV NS5B sofosbuvir resistance–associated variants
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
by Luetkemeyer, Anne F and McDonald, Cheryl and Ramgopal, Moti and Noviello, Stephanie and Bhore, Rafia and Ackerman, Peter
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1489 - 1496
Background. Highly effective hepatitis C virus (HCV) direct-acting antiviral therapies that do not require modification of human immunodeficiency virus (HIV)... 
HIV-HCV | sofosbuvir | coinfection | antiretroviral therapy | daclatasvir | INFECTIOUS DISEASES | THERAPY | PLUS SOFOSBUVIR | MICROBIOLOGY | INFECTION | IMMUNOLOGY | HIV-1 | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Viral Load | Young Adult | Adult | Female | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Drug Therapy, Combination | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Imidazoles - adverse effects | Antiviral Agents - administration & dosage | Coinfection - virology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Hepacivirus | Antiviral agents | Hepatitis | Usage | Care and treatment | Comorbidity | Analysis | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
by Chang, Christine Y and Chang, Christine Y and Nguyen, Pauline and Nguyen, Pauline and Le, An and Le, An and Zhao, Changqing and Zhao, Changqing and Ahmed, Aijaz and Ahmed, Aijaz and Daugherty, Tami and Daugherty, Tami and Garcia, Gabriel and Garcia, Gabriel and Lutchman, Glen and Lutchman, Glen and Kumari, Radhika and Kumari, Radhika and Nguyen, Mindie H and Nguyen, Mindie H
Medicine, ISSN 0025-7974, 2017, Volume 96, Issue 6, p. e6128
Real-life data on interferon (IFN)-free direct acting antiviral (DAA) therapies for chronic hepatitis C (CHC) is limited for Asian Americans. To evaluate... 
Asian Americans | Direct acting antivirals | Hepatitis C | Real-world experience | Sofosbuvir | VIRUS-INFECTION | hepatitis C | TAIWANESE PATIENTS | OPEN-LABEL | real-world experience | sofosbuvir | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | direct acting antivirals | SOFOSBUVIR PLUS RIBAVIRIN | PEGYLATED INTERFERON | PHASE-3 TRIAL | GENOTYPE 1 INFECTION | FIXED-DOSE COMBINATION | JAPANESE PATIENTS | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - ethnology | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Dose-Response Relationship, Drug | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Female | Aged | Retrospective Studies | Sofosbuvir - adverse effects | Sustained Virologic Response | Antiviral agents | Care and treatment | Liver diseases | Dosage and administration | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
by Jacobson, Ira M and Lawitz, Eric and Gane, Edward J and Willems, Bernard E and Ruane, Peter J and Nahass, Ronald G and Borgia, Sergio M and Shafran, Stephen D and Workowski, Kimberly A and Pearlman, Brian and Hyland, Robert H and Stamm, Luisa M and Svarovskaia, Evguenia and Dvory-Sobol, Hadas and Zhu, Yanni and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Bräu, Norbert and Berg, Thomas and Agarwal, Kosh and Bhandari, Bal Raj and Davis, Mitchell and Feld, Jordan J and Dore, Gregory J and Stedman, Catherine A.M and Thompson, Alexander J and Asselah, Tarik and Roberts, Stuart K and Foster, Graham R
Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
by Foster, Graham R and Irving, William L and Cheung, Michelle C.M and Walker, Alex J and Hudson, Benjamin E and Verma, Suman and McLauchlan, John and Mutimer, David J and Brown, Ashley and Gelson, William T.H and MacDonald, Douglas C and Agarwal, Kosh and HCV Res and HCV Research, UK
Journal of Hepatology, ISSN 0168-8278, 2016, Volume 64, Issue 6, pp. 1224 - 1231
Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver... 
Gastroenterology and Hepatology | Daclatasvir | Decompensated cirrhosis | MELD score | Hepatitis C virus | Sofosbuvir | Ledipasvir | MORTALITY | RIBAVIRIN | GENOTYPE 1 | HCV | INFECTION | TREAT | GASTROENTEROLOGY & HEPATOLOGY | DACLATASVIR PLUS SOFOSBUVIR | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Outcome Assessment (Health Care) | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Adult | Female | Aged | Retrospective Studies | Sustained Virologic Response | Antiviral agents | Care and treatment | Hepatitis C | Health aspects | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
by Poordad, Fred and Schiff, Eugene R and Vierling, John M and Landis, Charles and Fontana, Robert J and Yang, Rong and McPhee, Fiona and Hughes, Eric A and Noviello, Stephanie and Swenson, Eugene S
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, pp. 1493 - 1505
Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver transplantation recurrence represents a high unmet medical need with no... 
INTERFERON | THERAPY | PLUS SOFOSBUVIR | TIME | COMBINATION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | HCV INFECTION | DRUG-DRUG INTERACTIONS | LEDIPASVIR | Liver Cirrhosis - etiology | Recurrence | Prospective Studies | Liver Transplantation - adverse effects | Humans | Imidazoles - adverse effects | Middle Aged | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Confidence intervals | Genotype & phenotype | Hepatitis | Infections | Transplants & implants | Liver cirrhosis | Viral Hepatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
by Walsh, C. E and Workowski, K and Terrault, N. A and Sax, P. E and Cohen, A and Bowlus, C. L and Kim, A. Y and Hyland, R. H and Han, B and Wang, J and Stamm, L. M and Brainard, D. M and McHutchison, J. G and Drygalski, A and Rhame, F and Fried, M. W and Kouides, P and Balba, G and Reddy, K. R
Haemophilia, ISSN 1351-8216, 03/2017, Volume 23, Issue 2, pp. 198 - 206
Introduction: Chronic hepatitis C virus (HCV) infection is prevalent among patients with inherited bleeding disorders and is a leading cause of mortality in... 
sofosbuvir | hepatitis C virus | 5A inhibitor | ribavirin | ledipasvir–sofosbuvir fixed‐dose combination | 5B inhibitor | NS5A inhibitor | NS5B inhibitor | ledipasvir–sofosbuvir fixed-dose combination | UNITED-STATES | CHRONIC HCV | ledipasvir-sofosbuvir fixed-dose combination | FOLLOW-UP | ITALIAN PATIENTS | HEMOPHILIC PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | HIV-INFECTION | GENOTYPE 1 INFECTION | STAGE LIVER-DISEASE | HEMATOLOGY | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Fluorenes - therapeutic use | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Young Adult | Benzimidazoles - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Aged | Drug Combinations | Benzimidazoles - therapeutic use | Complications and side effects | Care and treatment | Mortality | Hemophilia | Blood diseases | Hepatitis C | Hepatitis C virus | Liver cirrhosis | Ribavirin | Headache | Liver | Diarrhea | Chronic infection | Fatigue | Infections | Nausea | Bleeding | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials
by Grebely, Jason and Mauss, Stefan and Brown, Ashley and Bronowicki, Jean-Pierre and Puoti, Massimo and Wyles, David and Natha, Macky and Zhu, Yanni and Yang, Junming and Kreter, Bruce and Brainard, Diana M and Yun, Chohee and Carr, Val and Dore, Gregory J
Clinical Infectious Diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1405 - 1411
Background. Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment... 
Hepatitis C virus | DAA | Drug use | PWID | Opioid substitution therapy | UNITED-STATES | INFECTIOUS DISEASES | METAANALYSIS | SOFOSBUVIR | MICROBIOLOGY | IMMUNOLOGY | LEDIPASVIR | HEPATITIS-C VIRUS | REINFECTION | hepatitis C virus | drug use | opioid substitution therapy | INJECT DRUGS | PEOPLE | USERS | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Drug Users | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Opiate Substitution Treatment | Retrospective Studies | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Data Interpretation, Statistical | Enzyme-Linked Immunosorbent Assay | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Sustained Virologic Response | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Treatment outcome | Safety and security measures | Analysis | Dosage and administration | Hepatitis C | Drug therapy | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment
by Welker, Martin-Walter and Luhne, Stefan and Lange, Christian M and Vermehren, Johannes and Farnik, Harald and Herrmann, Eva and Welzel, Tania and Zeuzem, Stefan and Sarrazin, Christoph
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 64, Issue 4, pp. 790 - 799
Graphical abstract 
Gastroenterology and Hepatology | HCV | Lactic acidosis | OLT | Ribavirin | Sofosbuvir | MITOCHONDRIAL TOXICITY | LIVER-TRANSPLANTATION PATIENTS | NATURAL-HISTORY | COMPENSATED CIRRHOSIS | HCV INFECTION | GENOTYPE 1 | TRANSIENT ELASTOGRAPHY | GASTROENTEROLOGY & HEPATOLOGY | DACLATASVIR PLUS SOFOSBUVIR | TREATMENT-NAIVE PATIENTS | PREVIOUSLY TREATED PATIENTS | Acidosis, Lactic - chemically induced | Liver Cirrhosis - drug therapy | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Hepatitis C virus | Liver cirrhosis | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Rapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers
by Elkady, Ehab F and Aboelwafa, Ahmed A
Journal of Chromatography B, ISSN 1570-0232, 12/2018, Volume 1102-1103, pp. 116 - 124
A novel, rapid and validated LC-MS/MS bioanalytical method has been developed for the extraction and determination of sofosbuvir and velpatasvir simultaneously... 
Sofosbuvir, velpatasvir, ledipasvir | Tandem mass | Bio-analytical method | ledipasvir | CHEMISTRY, ANALYTICAL | velpatasvir | BIOCHEMICAL RESEARCH METHODS | SIMULTANEOUS QUANTIFICATION | METABOLITE GS-331007 | Sofosbuvir | Reproducibility of Results | Fluorenes - analysis | Drug Stability | Humans | Sofosbuvir - blood | Egypt | Heterocyclic Compounds, 4 or More Rings - chemistry | Carbamates - blood | Linear Models | Benzimidazoles - analysis | Carbamates - pharmacokinetics | Carbamates - chemistry | Heterocyclic Compounds, 4 or More Rings - pharmacokinetics | Sensitivity and Specificity | Sofosbuvir - pharmacokinetics | Heterocyclic Compounds, 4 or More Rings - blood | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Drug Combinations | Sofosbuvir - chemistry | Ionization | Pharmacy | Formic acid | Drugstores | Nitriles | Precipitation (Meteorology) | Methods | Organic acids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials
by Grebely, Jason and Dore, Gregory J and Zeuzem, Stefan and Aspinall, Richard J and Fox, Raymond and Han, Lingling and McNally, John and Osinusi, Anu and Brainard, Diana M and Subramanian, G. Mani and Natha, Macky and Foster, Graham R and Mangia, Alessandra and Sulkowski, Mark and Feld, Jordan J
Clinical Infectious Diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1479 - 1481
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of... 
OST | HCV | Velpatasvir | Sofosbuvir | PWID | sofosbuvir | INFECTIOUS DISEASES | velpatasvir | HCV GENOTYPE 1 | MICROBIOLOGY | PEOPLE | RIBAVIRIN | IMMUNOLOGY | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Adult | Female | Opiate Substitution Treatment | Sofosbuvir - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Data Interpretation, Statistical | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - blood | Medication Adherence | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Sustained Virologic Response | Carbamates - therapeutic use | Hepatitis C, Chronic - genetics | Treatment outcome | Hepatitis C | Drug therapy | Analysis | Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
by Leroy, Vincent and Angus, Peter and Bronowicki, Jean‐Pierre and Dore, Gregory J and Hezode, Christophe and Pianko, Stephen and Pol, Stanislas and Stuart, Katherine and Tse, Edmund and McPhee, Fiona and Bhore, Rafia and Jimenez‐Exposito, Maria Jesus and Thompson, Alexander J
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, pp. 1430 - 1441
Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of... 
THERAPY | PROFILE | EFFICACY | PLUS SOFOSBUVIR | STEATOSIS | HCV GENOTYPE | INFECTION | PEGINTERFERON-ALPHA | TMC435 MONOTHERAPY | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Liver Cirrhosis - etiology | Humans | Imidazoles - adverse effects | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Genotype | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Hepacivirus - classification | Sofosbuvir - adverse effects | Drug Therapy, Combination | Life Sciences | Rapid Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
by Fontana, Robert J and Brown, Robert S and Moreno‐Zamora, Ana and Prieto, Martin and Joshi, Shobha and Londoño, Maria‐Carlota and Herzer, Kerstin and Chacko, Kristina R and Stauber, Rudolf E and Knop, Viola and Jafri, Syed‐Mohammed and Castells, Lluís and Ferenci, Peter and Torti, Carlo and Durand, Christine M and Loiacono, Laura and Lionetti, Raffaella and Bahirwani, Ranjeeta and Weiland, Ola and Mubarak, Abdullah and ElSharkawy, Ahmed M and Stadler, Bernhard and Montalbano, Marzia and Berg, Christoph and Pellicelli, Adriano M and Stenmark, Stephan and Vekeman, Francis and Ionescu‐Ittu, Raluca and Emond, Bruno and Reddy, K. Rajender and Medicinska fakulteten and Infektionssjukdomar and Institutionen för klinisk mikrobiologi and Umeå universitet
Liver Transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or... 
SURGERY | INTERFERON-ALPHA-2B | ANTIVIRAL THERAPY | RIBAVIRIN | COMBINATION | VIROLOGICAL RESPONSE | HCV INFECTION | TRANSPLANTATION | GENOTYPE 1 | PLUS SOFOSBUVIR | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | COMPASSIONATE USE | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Infectious Medicine | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Infektionsmedicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Ribavirin-Free Regimen with Sofosbuvir and Velpatasvir Is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients with Genotypes 2 and 3 Chronic Hepatitis C: Results from Astral-2 and -3 Clinical Trials
by Younossi, Zobair M and Stepanova, Maria and Sulkowski, Mark and Foster, Graham R and Reau, Nancy and Mangia, Alessandra and Patel, Keyur and Bräu, Norbert and Roberts, Stuart K and Afdhal, Nezam and Nader, Fatema and Henry, Linda and Hunt, Sharon
Clinical Infectious Diseases, ISSN 1058-4838, 10/2016, Volume 63, Issue 8, pp. 1042 - 1048
Background. Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and... 
Work productivity | Health-related quality of life | Fatigue | Hepatitis C | Direct-acting antivirals | ANTIVIRAL REGIMENS | INFECTIOUS DISEASES | VIRUS-INFECTION | work productivity | hepatitis C | MICROBIOLOGY | health-related quality of life | IMMUNOLOGY | LIVER-DISEASE | direct-acting antivirals | fatigue | PLUS SOFOSBUVIR | INSULIN-RESISTANCE | HCV | QUALITY-OF-LIFE | TELAPREVIR COMBINATION TREATMENT | TREATMENT-NAIVE PATIENTS | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Comorbidity | Humans |